Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer

Umberto Capitanio, MD
Published: Sunday, Nov 19, 2017



Umberto Capitanio, MD, FEBU, Department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

In the United States, sunitinib (Sutent) is now approved for the adjuvant treatment of this population. In Europe however, guidelines do not recommend the use of adjuvant therapy due to conflicting published results.
 


Umberto Capitanio, MD, FEBU, Department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

In the United States, sunitinib (Sutent) is now approved for the adjuvant treatment of this population. In Europe however, guidelines do not recommend the use of adjuvant therapy due to conflicting published results.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x